Literature DB >> 29601453

Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.

Nazario D Rivera-Chaparro1,2, Jessica Ericson3, Huali Wu1, P Brian Smith1,2, Reese H Clark4, Daniel K Benjamin1,2, Michael Cohen-Wolkowiez1,2, Rachel G Greenberg1,2.   

Abstract

Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 29601453      PMCID： PMC6163100          DOI： 10.1097/INF.0000000000002045

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   3.806


  8 in total

1.  The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system--tools for "meaningful use" in continuous quality improvement.

Authors:  Alan R Spitzer; Dan L Ellsbury; Darren Handler; Reese H Clark
Journal:  Clin Perinatol       Date:  2010-03       Impact factor: 3.430

2.  Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months.

Authors:  Daniel K Benjamin; Barbara J Stoll; Avory A Fanaroff; Scott A McDonald; William Oh; Rosemary D Higgins; Shahnaz Duara; Kenneth Poole; Abbot Laptook; Ronald Goldberg
Journal:  Pediatrics       Date:  2006-01       Impact factor: 7.124

Review 3.  Neonatal candidiasis: diagnosis, prevention, and treatment.

Authors:  Rachel G Greenberg; Daniel K Benjamin
Journal:  J Infect       Date:  2014-08-13       Impact factor: 6.072

4.  Population pharmacokinetics of micafungin in neonates and young infants.

Authors:  William W Hope; P Brian Smith; Antonio Arrieta; Donald N Buell; Michael Roy; Atsunori Kaibara; Thomas J Walsh; Michael Cohen-Wolkowiez; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

5.  High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.

Authors:  Cinzia Auriti; Marco Falcone; Maria Paola Ronchetti; Bianca Maria Goffredo; Sara Cairoli; Rosamaria Crisafulli; Fiammetta Piersigilli; Tiziana Corsetti; Andrea Dotta; Manjunath P Pai
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

6.  Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.

Authors:  Julie Autmizguine; Christoph P Hornik; Daniel K Benjamin; Kim L R Brouwer; Susan R Hupp; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Pediatr Infect Dis J       Date:  2016-11       Impact factor: 2.129

7.  Safety and Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance Study.

Authors:  Chie Kobayashi; Tomoko Hanadate; Toshiro Niwa; Takashi Yoshiyasu; Masahiro So; Keita Matsui
Journal:  J Pediatr Hematol Oncol       Date:  2015-07       Impact factor: 1.289

8.  Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study.

Authors:  Claudio Viscoli; Matteo Bassetti; Elio Castagnola; Simone Cesaro; Francesco Menichetti; Sandra Ratto; Carlo Tascini; Daniele Roberto Giacobbe
Journal:  BMC Infect Dis       Date:  2014-12-31       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.